ULTRALAN ® Fluocortolone

ULTRALAN ® is a drug based on Fluocortolone monohydrate and fluocortolone caproate.

THERAPEUTIC GROUP: Non-associated corticosteroids

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications ULTRALAN ® Fluocortolone

ULTRALAN ® is indicated in the treatment of dermatological diseases characterized by an inflammatory component and sensitive to topical treatment with corticosteroids.

Action mechanism ULTRALAN ® Fluocortolone

ULTRALAN ® is a drug based on Fluocortolone, an active ingredient belonging to the corticosteroid family, and therefore has a strong anti-inflammatory power, performed through the inhibition of the cascade of molecular events useful for the synthesis of inflammatory mediators such as prostaglandins, prostacyclins and thromboxanes.

The reduced production of these mediators results in a significant reduction of the inflammatory event with a more effective control of the typical symptomatology characterized by edema, redness and skin desquamation.

ULTRALAN ® also has particularly advantageous pharmacokinetic properties represented by the combination of two different esters of the same active principle, able therefore to effectively diffuse in the various layers of the skin persisting in place for different times.

The amount of drug absorbed will instead be effectively metabolised to the liver level and subsequently eliminated via the kidney.

Studies carried out and clinical efficacy

ISOCONAZOLE AND DIFLUCORTOLONE IN THE TREATMENT OF TINEA PEDIS

Mycoses. 2008 Sep; 51 Suppl 4: 48-9. doi: 10.1111 / j.1439-0507.2008.01609.x.

Study demonstrating the therapeutic success of the association between isoconazole and Difluocortolone in the treatment of Tinea pedis, thus highlighting the importance of topical corticosteroids in the treatment of dermatological diseases secondary to infections.

CHEMICAL STRUCTURE AND CLINICAL EFFICACY

J Drugs Dermatol. 2013 Feb; 12 (2): s3-4.

Monograph that demonstrates the clinical efficacy of Fluocortolone Pivalato, highlighting the importance of the chemical structure in improving the pharmacokinetic and pharmacodynamic properties as well as the safety of use.

THE IMPORTANCE OF DELIVERY SYSTEMS IN THE OPTIMIZATION OF THERAPEUTIC SUCCESS

Int J Nanomedicine. 2013; 8: 461-75. doi: 10.2147 / IJN.S40519. Epub 2013 Jan 30.

Interesting study that tests the effectiveness of nano particles of chitosan and lecithin in facilitating the release of fluocortolon at the site. These works highlight the importance of the delivery system in optimizing the therapeutic result.

Method of use and dosage

ULTRALAN ®

Cream for cutaneous use of 2.62 mg of Fluocortolone monohydrate and 2.5 mg of Fluocortolone caproate per gram of product.

The definition of the correct dosing schedule is the responsibility of the physician after a careful evaluation of the patient's general health conditions and the severity of his / her clinical picture.

In principle, the use of 2 -3 applications per day directly on the region to be treated could guarantee an improvement in symptoms in a few days of treatment, thus allowing the doctor to correct the dosage in the maintenance phase.

The use of the occlusive bandage should be prescribed by the doctor based on the patient's clinical condition.

Warnings ULTRALAN ® Fluocortolone

ULTRALAN ® therapy should be preceded by a careful medical examination to better characterize the patient's health conditions and any prescriptive appropriateness.

In order to reduce the incidence of possible side effects and to optimize the effectiveness of the therapy itself, the patient should comply with some basic health and hygiene regulations such as:

clean hands thoroughly after each application;
avoid applying the drug on large or severely damaged areas;
limit therapy as soon as possible;
avoid exposure of the treated area to ultraviolet radiation.

The presence in ULTRALAN ® of excipients such as stearyl alcohol, methyl parahydroxybenzoate and anhydrous lanolin, could cause unpleasant adverse reactions.

PREGNANCY AND BREASTFEEDING

The use of ULTRALAN ® during pregnancy and in the subsequent period of breastfeeding is generally contraindicated, given the absence of clinical trials capable of best characterizing the safety profile of topically applied Fluocortolone for fetal and infant health .

Interactions

At the present time, known pharmacological interactions are not known, although it should be remembered that the simultaneous intake of cytochrome inhibitor drugs may increase blood concentrations of the amount of corticosteroid absorbed.

ULTRALAN ® Fluocortolone Contraindications

The use of ULTRALAN ® is contraindicated in patients who are hypersensitive to the active ingredient or to one of its excipients, in patients with lesions associated with viral, bacterial and fungal infections not adequately treated or affected by rosacea and perioral dermatitis.

Undesirable effects - Side effects

ULTRALAN ® therapy, especially when it lasts for a long time, could lead to the appearance of local adverse reactions such as redness, burning, folliculitis, acneic eruptions, hypertrichosis, hypopigmentation and skin atrophy.

Definitely rarer are the systemic adverse reactions linked above all to the alteration of the hypothalamic-hypophyses-adrenal axis, mainly associated with the use of the medicine through an occlusive bandage.